Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Status:
Completed
Trial end date:
2016-10-17
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of alisertib when given together
with irinotecan hydrochloride in treating patients with advanced solid tumors or colorectal
cancer. Irinotecan hydrochloride and alisertib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)